個別化細胞療法市場：細胞タイプ別、治療領域別、エンドユーザー別、地域別

世界の個別化細胞療法市場は、2025年に175億9,000万米ドルと推定され、2032年には820億8,000万米ドルに達すると予測され、2025～2032年のCAGRは24.6%で成長する見込みです。

図.個別化細胞療法市場シェア（%）、2025年地域別

世界の個別化細胞療法市場の成長を牽引しているのは、様々な慢性疾患や生命を脅かす疾患を治療するための先進的な細胞療法を開発するための、主要企業による研究開発投資の増加です。個別化細胞療法は、治療効果を生み出すために患者自身の体から細胞を分離し、操作することを含みます。この新セグメントは、がん、神経疾患、心血管疾患などの治療法開発に有望です。ゲノミクス、細胞生物学、工学技術の進歩により、科学者たちは健康な状態や病気の状態で細胞がどのように機能するかについて理解を深めています。市場は、より多くの細胞治療製品が規制当局の承認を受け、臨床現場で採用されるにつれて成長する可能性があります。

市場力学

世界の個別化細胞療法市場の成長は、がんやその他の難病の有病率の上昇、慢性疾患に罹患しやすい高齢者の増加、再生医療の採用拡大、細胞療法の応用拡大、バイオテクノロジーの進歩、細胞ベースの研究に対する多額の投資など、いくつかの要因によって牽引されています。しかし、高い治療費、長い開発サイクル、臨床検査を取り巻く規制上のハードルが市場成長の妨げとなる可能性があります。iPSC（人工多能性幹細胞）技術の継続的研究、CAR T細胞療法の採用、同種細胞療法の研究開発、細胞療法の有効性に関するエビデンスの蓄積は、利害関係者に有利な機会を提供することができます。

本調査の主要特徴

• 本レポートでは、世界の個別化細胞療法市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の個別化細胞療法市場の主要企業をプロファイルしています。
• 本レポートから洞察は、マーケティング担当者や企業の経営陣が、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことを可能にすると考えられます。
• 世界の個別化細胞療法市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。
• 利害関係者は、世界の個別化細胞療法市場分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• 一貫型機会マップ（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 規制シナリオ
• 買収と提携のシナリオ
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の個別化細胞療法市場-コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界の個別化細胞療法市場、細胞タイプ別、2020～2032年（10億米ドル）

• イントロダクション
• リンパ球
• 間葉系幹細胞
• 造血幹細胞
• その他

第6章 世界の個別化細胞療法市場、治療領域別、2020～2032年（10億米ドル）

• イントロダクション
• 心血管疾患
• 神経疾患
• 炎症性疾患
• 糖尿病
• がん

第7章 世界の個別化細胞療法市場、エンドユーザー別、2020～2032年（10億米ドル）

• イントロダクション
• 病院
• 在宅医療
• 専門クリニック
• その他

第8章 世界の個別化細胞療法市場、地域別、2020～2032年（10億米ドル）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• 企業プロファイル
  • Thermo Fisher Scientific, Inc.
  • Novartis AG
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Bluebird Bio, Inc.
  • Personalis, Inc.
  • Adaptimmune Therapeutics PLC
  • BioNTech SE
  • Sangamo Therapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • CRISPR Therapeutics AG
  • Caribou Biosciences, Inc.
  • Mustang Bio, Inc.
  • Fate Therapeutics, Inc.
  • Atara BIoTherapeutics, Inc.
  • Holostem Terapie Avanzate Srl
• 隆盛と衰退
• 一貫型機会マップ

第10章 参考文献と調査手法

• 参考文献
• 調査手法

Global Personalized Cell Therapy Market is estimated to be valued at USD 17.59 Bn in 2025 and is expected to reach USD 82.08 Bn by 2032, growing at a compound annual growth rate (CAGR) of 24.6% from 2025 to 2032.

Figure. Personalized Cell Therapy Market Share (%), By Region 2025

Global personalized cell therapy market growth is driven by increasing R&D investments by key players in developing advanced cell therapies for treating various chronic and life-threatening diseases. Personalized cell therapy involves isolation and manipulation of cells from patient's own body to produce therapeutic effects. This emerging field holds promise for developing curative treatments for cancer, neurological disorders, cardiovascular diseases and others. With advancements in genomics, cell biology and engineering technologies, scientists are gaining deeper understanding of how cells function in healthy and diseased conditions, thus, allowing them to exploit cells' therapeutic potential in a personalized way. The market can witness growth as more cell therapy products receive regulatory approvals and get adopted in clinical practice.

Market Dynamics:

Global personalized cell therapy market growth is driven by several factors such as rising prevalence of cancer and other incurable diseases, growing geriatric population susceptible to chronic illnesses, increasing adoption of regenerative medicines, expanding applications of cell therapies, advances in biotechnology, and heavy investments in cell-based research. However, high treatment costs, long development cycles, and regulatory hurdles surrounding clinical trials can hamper the market growth. Ongoing research on iPSC (induced pluripotent stem cells) technology, adoption of CAR T-cell therapies, development of allogenic cell therapies, growing body of evidence on effectiveness of cell therapies can offer lucrative opportunities for stakeholders.

Key Features of the Study:

• This report provides in-depth analysis of the global personalized cell therapy market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global personalized cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Juno Therapeutics, Cellectis, Bellicum Pharmaceuticals, Vericel, Pharmicell, Pluristem Therapeutics, BioLineRx, Mesoblast.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global personalized cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global personalized cell therapy market.

Detailed Segmentation-

• By Cell Type
  • Lymphocytes
  • Mesenchymal Stem Cell
  • Hematopoietic Stem Cell
  • Others
• By Therapeutic Area
  • Cardiovascular Diseases
  • Neurological Disorders
  • Inflammatory Diseases
  • Diabetes
• By End Users
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Thermo Fisher Scientific, Inc.
  • Novartis AG
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Bluebird Bio, Inc.
  • Personalis, Inc.
  • Adaptimmune Therapeutics PLC
  • BioNTech SE
  • Sangamo Therapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • CRISPR Therapeutics AG
  • Caribou Biosciences, Inc.
  • Mustang Bio, Inc.
  • Fate Therapeutics, Inc.
  • Atara Biotherapeutics, Inc.
  • Holostem Terapie Avanzate S.r.l

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Cell Type
  • Market Snapshot, By Therapeutic Area
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Personalized Cell Therapy Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Personalized Cell Therapy Market, By Cell Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Lymphocytes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Mesenchymal Stem Cell
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hematopoietic Stem Cell
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Personalized Cell Therapy Market, By Therapeutic Area, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Cardiovascular Diseases
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neurological Disorders
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inflammatory Diseases
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Diabetes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Personalized Cell Therapy Market, By End Users, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Homecare
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Personalized Cell Therapy Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End Users, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • U.S.
  • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End Users, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End Users, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End Users, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End Users, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End Users, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

• Company Profiles
  • Thermo Fisher Scientific, Inc.
  • Company Highlights
  • Therapeutic Area Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Novartis AG
  • Company Highlights
  • Therapeutic Area Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Gilead Sciences, Inc.
  • Company Highlights
  • Therapeutic Area Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • Pfizer Inc.
  • Amgen Inc.
  • Bluebird Bio, Inc.
  • Personalis, Inc.
  • Adaptimmune Therapeutics PLC
  • BioNTech SE
  • Sangamo Therapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • CRISPR Therapeutics AG
  • Caribou Biosciences, Inc.
  • Mustang Bio, Inc.
  • Fate Therapeutics, Inc.
  • Atara Biotherapeutics, Inc.
  • Holostem Terapie Avanzate S.r.l
• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact

"